54 related articles for article (PubMed ID: 7525715)
1. Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor.
Chen TT; Tao MH; Levy R
J Immunol; 1994 Nov; 153(10):4775-87. PubMed ID: 7525715
[TBL] [Abstract][Full Text] [Related]
2. Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer.
Gillies SD; Lan Y; Brunkhorst B; Wong WK; Li Y; Lo KM
Cancer Immunol Immunother; 2002 Oct; 51(8):449-60. PubMed ID: 12202906
[TBL] [Abstract][Full Text] [Related]
3. Long-term immunity elicited by antibody-cytokine fusion proteins protects against sequential challenge with murine mammary and colon malignancies.
Helguera G; Rodríguez JA; Daniels TR; Penichet ML
Cancer Immunol Immunother; 2007 Sep; 56(9):1507-12. PubMed ID: 17310381
[TBL] [Abstract][Full Text] [Related]
4. TransitID: A unique ID to track proteins transiting within the cell and between cells.
Typas D
Nat Struct Mol Biol; 2023 Aug; 30(8):1060. PubMed ID: 37596468
[No Abstract] [Full Text] [Related]
5. A GMCSF-Neuroantigen Tolerogenic Vaccine Elicits Systemic Lymphocytosis of CD4
Moorman CD; Curtis AD; Bastian AG; Elliott SE; Mannie MD
Front Immunol; 2018; 9():3119. PubMed ID: 30687323
[TBL] [Abstract][Full Text] [Related]
6. Osteoclast fusion and regulation by RANKL-dependent and independent factors.
Xing L; Xiu Y; Boyce BF
World J Orthop; 2012 Dec; 3(12):212-22. PubMed ID: 23362465
[TBL] [Abstract][Full Text] [Related]
7. Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins.
López-Requena A; Burrone OR; Cesco-Gaspere M
Front Oncol; 2012; 2():159. PubMed ID: 23162790
[TBL] [Abstract][Full Text] [Related]
8. Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses.
Melchers M; Bontjer I; Tong T; Chung NP; Klasse PJ; Eggink D; Montefiori DC; Gentile M; Cerutti A; Olson WC; Berkhout B; Binley JM; Moore JP; Sanders RW
J Virol; 2012 Mar; 86(5):2488-500. PubMed ID: 22205734
[TBL] [Abstract][Full Text] [Related]
9. A GMCSF-neuroantigen fusion protein is a potent tolerogen in experimental autoimmune encephalomyelitis (EAE) that is associated with efficient targeting of neuroantigen to APC.
Blanchfield JL; Mannie MD
J Leukoc Biol; 2010 Mar; 87(3):509-21. PubMed ID: 20007248
[TBL] [Abstract][Full Text] [Related]
10. Progress and challenges in the vaccine-based treatment of head and neck cancers.
Venuti A
J Exp Clin Cancer Res; 2009 May; 28(1):69. PubMed ID: 19473517
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of immunotherapeutic effects of HPV16E7 on cervical cancer by fusion with CTLA4 extracellular region.
Zheng Y; Zhang Y; Ma Y; Wan J; Shi C; Huang L
J Microbiol; 2008 Dec; 46(6):728-36. PubMed ID: 19107404
[TBL] [Abstract][Full Text] [Related]
12. Advances in prostate cancer immunotherapies.
Basler M; Groettrup M
Drugs Aging; 2007; 24(3):197-221. PubMed ID: 17362049
[TBL] [Abstract][Full Text] [Related]
13. Cell-free production of scFv fusion proteins: an efficient approach for personalized lymphoma vaccines.
Kanter G; Yang J; Voloshin A; Levy S; Swartz JR; Levy R
Blood; 2007 Apr; 109(8):3393-9. PubMed ID: 17164345
[TBL] [Abstract][Full Text] [Related]
14. High efficient mammalian expression and secretion of a functional humanized single-chain Fv/human interleukin-2 molecules.
Shen YC; Wang XH; Wang XM; Chen ZL; Shen XP; Zhao CC; Li J
World J Gastroenterol; 2006 Jun; 12(24):3859-65. PubMed ID: 16804971
[TBL] [Abstract][Full Text] [Related]
15. Induction of anti B-cell malignance CTL response by subfamily-shared peptides derived from variable domain of immunoglobulin heavy chain.
Xiaoling G; Ying L; Jing L; Huifang L; Xia Z; Qingqing F; Ping Z
Cancer Immunol Immunother; 2005 Nov; 54(11):1106-14. PubMed ID: 15889252
[TBL] [Abstract][Full Text] [Related]
16. Vaccination strategies for lymphomas.
Dar MM; Kwak LW
Curr Oncol Rep; 2003 Sep; 5(5):380-6. PubMed ID: 12895388
[TBL] [Abstract][Full Text] [Related]
17. Comparison of adjuvant efficacy of herpes simplex virus type 1 recombinant viruses expressing TH1 and TH2 cytokine genes.
Osorio Y; Ghiasi H
J Virol; 2003 May; 77(10):5774-83. PubMed ID: 12719570
[TBL] [Abstract][Full Text] [Related]
18. Enhanced immunogenicity of pneumococcal surface adhesin A by genetic fusion to cytokines and evaluation of protective immunity in mice.
Gor DO; Ding X; Li Q; Schreiber JR; Dubinsky M; Greenspan NS
Infect Immun; 2002 Oct; 70(10):5589-95. PubMed ID: 12228286
[TBL] [Abstract][Full Text] [Related]
19. Native IgG2a(b) is barely antigenic to major histocompatibility complex class II-restricted T cells owing to inefficient internalization by professional antigen-presenting cells.
Bartnes K; Hannestad K
Immunology; 2000 Apr; 99(4):510-22. PubMed ID: 10792498
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
